This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Rutgers, The State University of New Jersey. Active years: 2018-2023.
Company Filing History:
6 out of 165 
4 out of 15 
3 out of 1,494 
Years Active: 2018-2023
Title: Innovations in Tumor Treatment by Inventor Xiangzhong Ye
Introduction
Xiangzhong Ye is a prominent inventor based in Beijing, China. He has made significant contributions to the field of medical research, particularly in the treatment of tumors. With a total of six patents to his name, his work focuses on utilizing viruses for therapeutic purposes.
Latest Patents
Xiangzhong Ye's latest patents include innovative approaches to tumor treatment using enterovirus D68 (EV-D68) and echovirus 25 (ECHO25). The patent for EV-D68 outlines the use of this virus or its modified forms, along with nucleic acid molecules, in the manufacture of pharmaceutical compositions aimed at treating tumors. Similarly, his patent for ECHO25 describes its application in the treatment of tumors and the development of medicaments for this purpose.
Career Highlights
Throughout his career, Xiangzhong Ye has worked with notable institutions such as Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. His research has garnered attention for its potential to revolutionize cancer treatment through viral therapies.
Collaborations
Xiangzhong Ye has collaborated with esteemed colleagues, including Ningshao Xia and Tong Cheng, to advance his research and innovations in the field.
Conclusion
Xiangzhong Ye's contributions to tumor treatment through innovative viral therapies highlight his role as a leading inventor in medical research. His patents reflect a commitment to developing effective solutions for cancer treatment.